@article{JTD10616,
author = {Victor Serebruany and Naida Bulaeva and Elena Golukhova},
title = {Ticagrelor and heart surgery controversy: we may have better antiplatelet options},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {11},
year = {2016},
keywords = {},
abstract = {Despite advanced techniques and favorable clinical outcomes, the optimal antiplatelet strategy following coronary artery bypass grafting (CABG) is an unsolved mystery. Development of novel antiplatelet agents is pivotal for the management of patients with clinically evident coronary atherothrombosis in general, and those requiring CABG in particular. In contrast to the percutaneous coronary interventions, and stent implantations where aggressive antiplatelet strategies are conventional, the protection over CABG is a matter of considerable controversy with regard to the choice of optimal agent(s), potential dose adjustment, duration of therapy, and, most importantly, need for discontinuation during surgery (1,2).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/10616}
}